Sponsored message
Audience-funded nonprofit news
radio tower icon laist logo
Next Up:
0:00
0:00
Subscribe
  • Listen Now Playing Listen
News

How The DEA's New Marijuana Classification Could Affect California's Cannabis Industry

Packaging for a marijuana cigarette sits on top of dried cannabis flowers.
The U.S. Drug Enforcement Administration (DEA) announced plans to reclassify marijuana as a less dangerous drug and designate it a Schedule III controlled substance instead of a Schedule I drug where it is currently listed.
(
Justin Sullivan
/
Getty Images
)

With our free press under threat and federal funding for public media gone, your support matters more than ever. Help keep the LAist newsroom strong, become a monthly member or increase your support today.

Listen 9:56
US May Ease Marijuana Restrictions – How Could This Affect California
The U.S. Drug Enforcement Administration will move to reclassify marijuana as a less dangerous drug, a historic shift to generations of American drug policy that could have wide ripple effects across the country. The DEA’s proposal, which still must be reviewed by the White House Office of Management and Budget, would recognize the medical uses of cannabis and acknowledge it has less potential for abuse than some of the nation’s most dangerous drugs. However, it would not legalize marijuana outright for recreational use. The agency’s move clears the last significant regulatory hurdle before the agency’s biggest policy change in more than 50 years can take effect. Once OMB signs off, the DEA will take public comment on the plan to move marijuana from its current classification as a Schedule I drug, alongside heroin and LSD. It moves pot to Schedule III, alongside ketamine and some anabolic steroids, following a recommendation from the federal Health and Human Services Department. After the public comment period and a review by an administrative judge, the agency would eventually publish the final rule. What does this mean for the California Cannabis industry? Joining us to discuss is Richard Ormond, shareholder at Buchalter, a West Coast-based law firm, where he founded their cannabis law practice group, and the current receiver for MedMen Enterprises, which went into receivership last week. Also joining is Jerred Kiloh, owner of the Higher Path Collective in Sherman Oaks and chairman of the United Cannabis Business Association.

The U.S. Drug Enforcement Administration is considering reclassifying marijuana from a Schedule I drug to Schedule III. Schedule III drugs, while still controlled substances, are treated differently under the law from Schedule I drugs, which, according to the DEA, have “no currently accepted medical use and a high potential for abuse.”

How could this new classification affect California’s legal cannabis industry? On LAist’s daily news show AirTalk, host Larry Mantle spoke with stakeholders to find out.

The tax man cometh

The biggest benefit of the reclassification of marijuana could come from the IRS. A new classification could allow cannabis businesses to deduct expenses that they currently can’t.

Sponsored message

“Right now, they tax these businesses as illegal businesses, and they're not allowed to depreciate or deduct most of their costs,” said Richard Ormond, shareholder at Buchalter, a West Coast-based law firm, where he founded their cannabis law practice group.

Jerred Kiloh, owner of the Higher Path Collective in Sherman Oaks and chairman of the United Cannabis Business Association, is optimistic.

“I just look at my own individual business and I see probably around ... $250,000 a year in federal taxes that I will be able to deduct like a normal business expense, which seems like a really big deal for a company that is just a mom-and-pop trying to make it.”

But Ormond sounded a note of caution. “Until the tax scheme changes, a lot of these businesses are going to be overburdened with licensing fees, taxes, and other government obligations that they have to pay,” he said. “I don't think the tax code is going to be reformed for quite a while.”

Unlocking research

In a statement, Director of the California Department of Cannabis Control Nicole Elliot applauded the DEA’s move, “It will enable new scientific research, so that we can better understand cannabis’ medical value—and also its potential risks.”

Sponsored message

UCBA's Kiloh echoed the potential benefits of new research.

“This can only signal to consumers that we're doing more to protect you, we're doing more to understand this plant and its effects on your body, and then that will then signal people to enter the industry with a little less trepidation.”

All the way to the bank

Banking is a significant pain point for businesses selling marijuana, as major banks and payment processors don’t allow cannabis transactions. Kiloh thinks the federal government softening its attitude towards cannabis could “start to signal to credit card companies and banks and processors that … they can move some of their policies away from being so stringent.”

Baby steps

“[Reclassification] is step one of about eight steps that the federal government needs to take to make this a real viable industry,” explained Ormond. According to him, crucial next steps towards a thriving cannabis industry include Congress enacting a safe banking statute and robust interstate commerce. “For this to be a real viable industry, you have to open up those interstate commerce channels.”

What's next

The proposal will be studied by the White House Office of Management and Budget before entering a 60-day public comment period. Lastly, an administrative judge would need to sign off on the decision.

Sponsored message

Listen to the conversation

Listen 9:56
US May Ease Marijuana Restrictions – How Could This Affect California

Trending on LAist